Article Text

Download PDFPDF

Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne)
  1. N Mandal,
  2. I H Chisholm
  1. Southampton Eye Unit
  1. Correspondence to: Nakul Mandal, c/o Sheila Davies, Southampton Eye Unit, Southampton SO16 6YD, UK; nm397{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Verteporfin has recently been licensed for the treatment of subfoveal exudative cases of age related macular degeneration (AMD); however, it is not clear how many patients would actually benefit from this treatment.1,2 This question has far reaching implications in terms of verteporfin's introduction into the National Health Service in the United Kingdom.

Case report

We have recently looked at a cohort of 1418 new referrals (out of a possible 1481 (95.7%)) seen in the 166 consultant outpatient clinics at Southampton Eye Unit, between 1 December 2000 and 31 January 2001. Diagnoses were obtained from the consultant's letter to the referring doctor following the clinic visit to obtain the spectrum of diagnoses made. When two eyes were similarly affected this was recorded as a single diagnostic event.

Cataract related diagnoses3 were found to be most frequent, accounting for 28.8% (597) …

View Full Text